This study will enroll patients with KRASG12C mutant NSCLC not previously treated with KRASG12C inhibitors. Patients in this study will receive ladarixin and sotorasib. The primary objective of the Phase II portion is to evaluate progression free survival (PFS).
This is a phase II, open-label, study of twice-daily oral ladarixin in patients with advanced KRAS G12C mutant non-small cell lung cancer (NSCLC) with sotorasib.